Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts
07:00pm, Wednesday, 08'th Apr 2026
Gilead Sciences (GILD) reached $141.54 at the closing of the latest trading day, reflecting a +1.97% change compared to its last close.
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Wednesday, 08'th Apr 2026
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
12:06am, Wednesday, 08'th Apr 2026
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
10:27am, Tuesday, 07'th Apr 2026
Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company EQT Life Sciences led the Series B2 financing of Tubulis in Ma
Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion
09:14am, Tuesday, 07'th Apr 2026
Gilead Sciences agrees to buy German biotech company Tubulis for $3.15 billion upfront and $1.85 billion in contingency payments.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
08:50am, Tuesday, 07'th Apr 2026
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company's oncology pipeline.
FOSTER CITY, Calif. & MUNICH--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinica
Gilead to acquire Tubulis GmbH for up to $5 billion
08:23am, Tuesday, 07'th Apr 2026
Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, boosting the U.S. drugmaker's pipeline with a lucrative class of exper
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
04:11pm, Monday, 06'th Apr 2026
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Leo Wealth LLC Purchases 3,680 Shares of Gilead Sciences, Inc. $GILD
06:57am, Monday, 06'th Apr 2026
Leo Wealth LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 32.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchan
Gilead Sciences, Inc. $GILD Position Reduced by Aberdeen Group plc
03:05am, Friday, 03'rd Apr 2026
Aberdeen Group plc trimmed its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 12.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and E
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
10:01am, Thursday, 02'nd Apr 2026
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $10.37 Million Stake in Gilead Sciences, Inc. $GILD
05:30am, Thursday, 02'nd Apr 2026
Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 7.6% in the undefined quarter, according to its most recent
Banque Pictet & Cie SA Purchases 142,543 Shares of Gilead Sciences, Inc. $GILD
04:45am, Thursday, 02'nd Apr 2026
Banque Pictet and Cie SA raised its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 168.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exc
Gilead Extends Tender Offer to Acquire Arcellx
04:13pm, Wednesday, 01'st Apr 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer re
